Expression of Urokinase-Type Plasminogen Activator (uPA), its Receptor (uPAR), and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 2, 2012, Pages 93-103

  Andres, Sarah A ^a   Edwards, Angelena B ^a   Wittliff, James L ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Breast carcinoma; Estrogen receptor; PAI 1; Progestin receptor; UPA; UPAR

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; PROTEIN EXPRESSION; RACE; RADIOASSAY; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SURVIVAL ANALYSIS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84859203369     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21488     Document Type: Article

References (44)

1. Lester SC. The Breast. In: V Kumar, AK Abbas, N Fausto, editors. Robbins and Cotran Pathological Basis of Disease. Philadelphia, PA: Elsevier Inc; 2005. p 1119-1154.
2. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993;73:161-195.
3. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C. Plasminogen activators in human malignant melanoma. J Natl Cancer Inst 1984;72:1213-1222.
4. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997;72:1-22.
5. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988;62:531-533.
6. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-6829.
7. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-6105.
8. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-Van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-643.
9. Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 1991;17:303-312.
10. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
11. Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 1991;51:3522-3525.
12. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-873.
13. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-2907.
14. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344:583-584.
15. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54:6539-6548.
16. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F, Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994;55:401-409.
17. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int J Gynecol Cancer 2000;10:372-381.
18. Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol Oncol 2001;80:48-55.
19. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-492.
20. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS. Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 1994;22:101-110.
21. Choong PF, Ferno M, Akerman M, Willen H, Langstrom E, Gustafson P, Alvegard T, Rydholm A. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 1996;69:268-272.
22. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996;77:1079-1088.
23. Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Cancer 2004;101:486-494.
24. Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Janicke F, Thomssen C. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002;3:196-200.
25. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002;20:1000-1007.
26. Wittliff JL, Pasic R, Bland KI. Steroid and peptide hormone receptors: Methods, quality control, and clinical use. In: K Bland, E Copeland, editors. The Breast: Comprehensive Management of Benign and Malignant Diseases. Philadelphia: W.B. Saunders Co.; 1998. p 458-498.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-1184.
28. Pasic R, Djulbegovic B, Wittliff JL. Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding. J Clin Lab Anal 1990;4:430-436.
29. Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137-147.
30. Sanfilippo JS, Miseljic S, Yang AR, Doering DL, Shaheen RM, Wittliff JL. Quantitative analyses of epidermal growth factor receptors, HER-2/neu oncoprotein and cathepsin D in nonmalignant and malignant uteri. Cancer 1996;77:710-716.
31. Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, Bronger H, Hofler H, Becker KF. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: New insights from protein microarray analysis. J Pathol 2011;223:54-63.
32. Stavraky K, Emmons S. Breast cancer in premenopausal and postmenopausal women. J Natl Cancer Inst 1974;53:647-654.
33. Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 2002;72:107-115.
34. Zheng W, Wen W, Gao YT, Shyr Y, Zheng Y, Long J, Li G, Li C, Gu K, Cai Q, Shu XO, Lu W. Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst 2010;102:972-981.
35. Bird Y, Moraros J, Banegas MP, King S, Prapasiri S, Thompson B. Breast cancer knowledge and early detection among Hispanic women with a family history of breast cancer along the U.S.-Mexico border. J Health Care Poor Underserved 2010;21:475-488.
36. Kapp JM, Walker R, Haneuse S, Buist DS, Yankaskas BC. Are there racial/ethnic disparities among women younger than 40 undergoing mammography? Breast Cancer Res Treat 2010;124:213-222.
37. Witzel ID, Milde-Langosch K, Wirtz RM, Roth C, Ihnen M, Mahner S, Zu EC, Janicke F, Muller V. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome. J Cancer Res Clin Oncol 2010;136:1709-1718.
38. Levicar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovic-Grazio S, Lah TT. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect Prev 2002;26:42-49.
39. Tong D, Czerwenka K, Sedlak J, Schneeberger C, Schiebel I, Concin N, Leodolter S, Zeillinger R. Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines. Breast Cancer Res Treat 1999;56:91-97.
40. Kotzsch M, Bernt K, Friedrich K, Luther E, Albrecht S, Gatzweiler A, Magdolen V, Baretton G, Zietz C, Luther T. Prognostic relevance of tumour cell-associated uPAR expression in invasive ductal breast carcinoma. Histopathology 2010;57:461-471.
41. Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sutterlin M, Marx A, Stroebel P. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: Prognostic impact. Histol Histopathol 2009;24:869-877.
42. Hurd TC, Sait S, Kohga S, Winston J, Martinick M, Saxena R, Lankes H, Markus G, Harvey S, Gibbs JF. Plasminogen activator system localization in 60 cases of ductal carcinoma in situ. Ann Surg Oncol 2007;14:3117-3124.
43. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001;93:913-920.
44. Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Kruger A, Kiechle M, Janicke F, Schmitt M, Foekens JA. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 2002;62:4617-4622.